Articles from 2025

SunHydrogen news for website.png

SunHydrogen Achieves Live Demonstration of Commercial-Size Hydrogen Module

Tuesday, August 12, 2025
SunHydrogen has successfully demonstrated live operation of its commercial-size 1.92m² hydrogen module, producing renewable hydrogen using only sunlight and water. This major milestone showcases the scalability and off-grid potential of the company’s renewable hydrogen production technology.
IDT.jpg

Integrated DNA Technologies Announces Translational CRISPR Portfolio Expansion with Product Innovation Updates

Friday, July 18, 2025
New purity offering, off-target analysis services and additional solutions help to bridge the gap from discovery research to clinical translation and advance CRISPR-based therapies
IDT.jpg

IDT: The Original Innovator in Gene Fragments, Leadership through Science and Quality

Monday, July 14, 2025
IDT launches all-inclusive gene fragments from 7 cents per base with 25% lower turnaround times and next-day shipping powered by its cutting-edge synthetic biology facility
IDT.jpg

Integrated DNA Technologies Announces Innovation Roadmap Advances to Infectious Disease Portfolio

Expanded portfolio offerings include first-to-market product launches to support global health challenges New infectious disease research solutions to be spotlighted at ASM Microbe 2025
Perspective Therapeutics.jpg

Perspective Therapeutics Brings Energy to the Radiopharma World

The Seattle-based company came to ASCO25 with new data on its neuroendocrine tumor–treating lead therapy, with big vibes and speedy speech.
Pani Clean.jpeg

Pani Clean Installs Off-Grid Nitrate-to-Ammonia Pilot Unit at the Iowa Wastewater and Waste to Energy Research Program (IWWERP) Tech Park

Monday, June 9, 2025
A solar-powered nitrate treatment unit is installed to demonstrate circular resource recovery
IDT.jpg

Integrated DNA Technologies, Aldevron pioneer first personalized CRISPR therapy powered by mRNA

Tuesday, May 20, 2025
Aldevron and Integrated DNA Technologies – both part of the Danaher Corporation – have achieved a medical milestone with the successful manufacture of the world’s first personalized CRISPR gene-editing drug product to treat an infant suffering from a rare and life-threatening genetic condition known as urea cycle disorder (UCD).